This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Apolipoprotein E (apo E) in Alzheimer's disease

Authoring team

Apolipoprotein E4 confers a dose-related risk for developing Alzheimer's disease.

There is experimental evidence which permits estimation of the size of the risk:

  • the possession of apoE4 confers a 2.27 fold relative risk for Alzheimer's disease over homozygotes for the common apoE3 polymorphism

  • the increased risk is only significant for patients presenting between the ages of 60 and 70; in older patients, representing 60% of cases, apoE4 is not a risk factor for Alzheimer's disease

  • homozygosity for apoE4 is a greater risk than heterozygosity; despite this a survey of apoE4 homozygotes with an average age of 81 demonstrated that 85% were unimpaired on mental status tests

  • APOE4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses (4)

Reference:

  • 1) Evans, DA, Beckett, LA, Field, TS et al. (1997) Apolipoprotein E4 and incidence of Alzheimer's disease in a community population of older persons. JAMA, 277,822.
  • 2) Blacker, D, Haines, JL, Rodes, L et al. (1997) APOE-4 and age of onset of Alzheimer's disease: the NIMH genetics initiative. Neurology, 48, 139.
  • 3) Hyman, BT, Gomez-Isla, T, Brigg, M. et al. (1996) Apolipoprotein E4 and cognitive change in an elderly population. Ann Neurol, 40, 55.
  • 4) Kunkle BW et al.Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing.Nat Genet. 2019; 51: 414-430

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.